Veracyte, Inc. - VCYT STOCK NEWS

Veracyte (VCYT) announces findings published in Frontiers in Endocrinology, revealing insights into the frequency and risk of malignancy linked to thyroid stimulating hormone receptor (TSHR) mutations in indeterminate thyroid nodules. Analysis of 8,881 nodules showed that only 5% were classified as suspicious for cancer. The risk of malignancy for benign nodules is ≤4%, while those identified as suspicious by the Afirma Genomic Sequencing Classifier (GSC) have a 15.3% risk. These results underscore the potential of Afirma testing for personalized care in thyroid nodule diagnosis and treatment.

Veracyte (Nasdaq: VCYT) announced a meta-analysis confirming the Afirma Genomic Sequencing Classifier (GSC) performs strongly in real-world settings. This analysis, involving 1,976 patients with indeterminate thyroid nodules (ITNs), shows the Afirma GSC's ability to rule out benign nodules with a sensitivity of 97% and a negative predictive value of 99%. The test's predictive ability for malignant nodules also improved, with a 65% positive predictive value. This supports the test's role in reducing unnecessary surgeries and guiding timely treatment decisions.

Veracyte reported strong financial results for Q3 2022, with total revenue of $75.6 million, a 25% increase year-over-year. Total test volume rose by 26% to 26,374 tests. The company secured new coverage for its Decipher Prostate test, expanding its reach to 195 million covered lives. Gross margin improved to 59%, and net loss reduced to $8.7 million, a 38% improvement. Veracyte raised its full-year 2022 revenue outlook to $288 million to $293 million, reflecting 31% to 33% growth compared to 2021.

Veracyte (NASDAQ: VCYT) announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's 37th Annual Meeting, showcasing its multi-omics capabilities in immuno-oncology. These abstracts highlight the potential of the Veracyte Biopharma Atlas and Brightplex offerings for enhancing the understanding of tumor microenvironments, aiding biopharma partners in oncology drug development. The meeting will take place from November 8-12, 2022, in Boston, where Veracyte will also host a symposium to discuss its Biopharma Atlas.

Veracyte, Inc (Nasdaq: VCYT) announced that CEO Marc Stapley and CFO Rebecca Chambers will engage in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on November 8 at 1:25 p.m. ET. A live audio webcast will be accessible on Veracyte's website, with a replay available for 90 days post-event. Veracyte is a global diagnostics company focused on improving patient care through advanced diagnostic tests, helping avoid unnecessary procedures and expedite treatment.

Veracyte (Nasdaq: VCYT) presented new data at the ASTRO Annual Meeting 2022, indicating that a genomic signature from its Decipher GRID database can predict which men benefit from dose-intensified salvage radiotherapy (SRT) after prostate cancer surgery. In a phase 3 trial involving 226 men, those with higher PORTOS scores saw a 45% increase in clinical-progression-free survival (CPFS) at five years with SRT, as opposed to an observed -10% in those with lower scores. This predictive biomarker could aid in personalizing treatment for prostate cancer patients post-surgery.

Veracyte, Inc. (Nasdaq: VCYT) has shared new insights into thyroid tumor behavior derived from their extensive thyroid nodule database. Presenting at the American Thyroid Association Annual Meeting, researchers reviewed over 300 pathology reports, revealing a negative predictive value for low-risk nodules of 95%. The Afirma Genomic Sequencing Classifier (GSC) identified a higher malignancy risk of 15.3% in nodules with TSHR mutations, compared to <1.5% for benign classifications. These findings emphasize the potential for improved personalized treatment decisions.

Veracyte (NASDAQ: VCYT) presented key findings at the CHEST Annual Meeting 2022, demonstrating the clinical value of its Envisia Genomic Classifier and Percepta Nasal Swab tests. The Envisia test identified genomic patterns indicating progressive disease in patients with interstitial lung disease (ILD), showing a significant decline in lung function among positive cases. Meanwhile, initial data for the Percepta Nasal Swab test suggested improved risk stratification for lung cancer in patients with nodules. These innovations aim to enhance patient care and assist physicians in making informed treatment decisions.

Veracyte, Inc. (Nasdaq: VCYT) announced it will release its third quarter 2022 financial results on November 2, 2022, after market close. Management plans to host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The call will be available via webcast on the company's website. Veracyte focuses on improving patient care with advanced diagnostic tests that help avoid unnecessary procedures and reduce treatment time, with operations based in South San Francisco, California.